1544739-64-1

Basic information

• Product Name: (4-fluoro-tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate
• Synonyms: (4-fluoro-tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate
• CAS NO: 1544739-64-1
• Molecular Weight: 288.34
• Mol File: 1544739-64-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (4-fluoro-tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: (4-fluoro-tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate(1544739-64-1)
• EPA Substance Registry System: (4-fluoro-tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate(1544739-64-1)

Safety Data

• Hazardous Substances Data: 1544739-64-1(Hazardous Substances Data)

Upstream product

• 883442-46-4 (4-fluorotetrahydro-2H-pyran-4-yl) methanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 1544739-62-9 4-((ethylperoxy)methyl)-4-fluorotetrahydro-2H-pyran 
• 1544739-63-0 C₈H₁₆O₃ 

Downstream Products

• 1544739-68-5 ethyl 3-((4-fluoro-4’-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-2’,6’-dimethyl-[1,1’-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylate 
• 1544739-61-8 (5aR,6S,6aS)-3-((4-fluoro-4’-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-2’,6’-dimethyl-[1,1‘-biphenyl]-3-yl)methoxy)-5,5a,6,6a-tetrahydrocyclopropa[4,5]cyclopenta[1,2-c]pyridine-6-carboxylic acid 
• 1544739-65-2 4-((4-bromo-3,5-dimethylphenoxy)methyl)-4-fluorotetrahydro-2H-pyran 

Relevant articles and documents

AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound, and the 8-substituted styryl xanthine derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.